ARS Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
ARS Pharmaceuticals has a total shareholder equity of $256.8M and total debt of $69.4M, which brings its debt-to-equity ratio to 27%. Its total assets and total liabilities are $351.2M and $94.4M respectively.
Key information
27.0%
Debt to equity ratio
US$69.38m
Debt
| Interest coverage ratio | n/a |
| Cash | US$314.02m |
| Equity | US$256.80m |
| Total liabilities | US$94.36m |
| Total assets | US$351.15m |
Recent financial health updates
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13
We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Recent updates
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
Feb 06ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Financial Position Analysis
Short Term Liabilities: SPRY's short term assets ($334.3M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: SPRY's short term assets ($334.3M) exceed its long term liabilities ($70.9M).
Debt to Equity History and Analysis
Debt Level: SPRY has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SPRY's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SPRY's debt is not well covered by operating cash flow (19.5%).
Interest Coverage: Insufficient data to determine if SPRY's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 03:13 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ARS Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Andreas Argyrides | Oppenheimer & Co. Inc. |